Clear Street Starts Moonlake Immunotherapeutics (MLTX) at Buy

Clear Street analyst Kaveri Pohlman initiates coverage on Moonlake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and a price target of $108.00.

The analyst comments "We are initiating coverage on Moonlake with a Buy rating and a $108 PT. We believe that sonelokimab’s (SLK’s) best-in-class profile, blockbuster potential (peak est. sales = $5B+), and upcoming results from multiple pivotal trials lay a strong foundation for upside."

For an analyst ratings summary and ratings history on Moonlake Immunotherapeutics click here. For more ratings news on Moonlake Immunotherapeutics click here.

Shares of Moonlake Immunotherapeutics closed at $53.54 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Critical One Energy closes second tranche of flow-through placement